Phosphodiesterase-5 inhibitors: Future perspectives

Current Pharmaceutical Design

Volumn 15, Issue 30, 2009, Pages 3540-3551

  Konstantinos, Giannitsas ^a   Petros, Perimenis ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Future; Indications; Phosphodiesterase 5 inhibitors; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CISPLATIN; CLONIDINE; FLUOXETINE; LODENAFIL; LODENAFIL CARBONATE; MIRODENAFIL; MORPHINE; PACLITAXEL; PAROXETINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; UDENAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; EVENING DOSAGE; FEMALE SEXUAL DYSFUNCTION; GASTRIC DYSMOTILITY; GENE EXPRESSION; GLIOSARCOMA; GLOMERULONEPHRITIS; HEART HYPERTROPHY; HEART INFARCTION; HEART PROTECTION; HUMAN; LIPID PEROXIDATION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MEMORY DISORDER; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PAIN; PREECLAMPSIA; PREMATURE EJACULATION; PRIAPISM; PRIORITY JOURNAL; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; REPEATED DRUG DOSE; REVIEW; SEXUAL SATISFACTION; SICKLE CELL ANEMIA; SINGLE DRUG DOSE; SPERMATOZOON COUNT; SPERMATOZOON MOTILITY; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WOUND HEALING;

ANIMALS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; ERECTILE DYSFUNCTION; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PREGNANCY; UROLOGIC DISEASES;

EID: 70449448955     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789206953     Document Type: Review

References (134)

1. Lin CS, Lin G, Xin ZC, Lue TF. Expression, distribution and regulation of phosphodiesterase 5. Curr Pharm Des 2006; 12(27): 3439-3457
2. Kim YH, Choi H, Lee J, Hwang IC, Moon SK, Kim SJ, et al. Quinazolines as potent and highly selective PDE5 inhibitors as potential therapeutics for male erectile dysfunction. Bioorg Med Chem Lett 2008; 18(23): 6279-6282
3. Bunnage ME, Mathias JP, Wood A, Miller D, Street SD. Highly potent and selective chiral inhibitors of PDE5: an illustration of Pfeiffer's rule. Bioorg Med Chem Lett 2008; 18(23): 6033-6036
4. Paick JS, Ahn TY, Choi HK, Chung WS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008; 5(11): 2672-2680
5. Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol 2008; 591(1-3): 189-195
6. Glina S, Toscano I, Gomatzky C, de Góes PM, Júnior AN, Claro JF,et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009; 6(2): 553-557
7. Paick JS, Kim SW, Yang DY, Kim JJ, Lee SW, Ahn TY, et al. The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction. J Sex Med 2008; 5(4): 946-953
8. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. Int J Impot Res 2009; 21(2): 122-128
9. Mulhall JP, Müller A, Donohue JF, Mullerad M, Kobylarz K, Paduch DA, et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med 2008; 5(5): 1126-1136 (Pubitemid 351606701)
10. Iacono F, Prezioso D, Somma P, Chierchia S, Galasso R, Micheli P. Histopathologically proven prevention of post-prostatectomy cavernosal fibrosis with sildenafil. Urol Int 2008; 80(3): 249-52.
11. Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, Montorsi F, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res 2008; 20(5): 479-486
12. McCullough AR, Levine LA, Padma-Nathan H. Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial. J Sex Med 2008; 5(2): 476-484
13. Bannowsky A, Schulze H, van der Horst C, Hautmann S, Jünemann KP. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int 2008; 101(10): 1279-83.
14. Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008; 54(4): 924-931
15. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3(4): 662-667 (Pubitemid 43919020)
16. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 2007; 177(3): 1071-1077 (Pubitemid 46216352)
17. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177(4): 1401-1407 (Pubitemid 46435965)
18. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180(4): 1228-1234
19. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51(6): 1717-1723
20. McVary KT, Siegel RL, Carlsson M. Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 2008; 72(3): 575-9.
21. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernández C, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008; 5(9): 2170-2178
22. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53(6): 1236-1244
23. Guven EO, Balbay MD, Mete K, Serefoglu EC. Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. Int Urol Nephrol 2008; 41(2): 287-292
24. Eli Lilly and Company. A phase 3, randomized, double-blind, placebo-controlled, parallel-design, multinational study to evaluate the efficacy and safety of daily tadalafil for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia. www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [Cited 2009 April; 21] Available from: http: //Clinical Trials.gov/show/NCT00827242 NLM Identifier: NCT00827242.
25. Eli Lilly and Company. A phase 2, randomized, double-blind, placebo-controlled, parallel-design study to evaluate the efficacy and safety of tadalafil once-a-day dosing for 12 weeks followed by an open-label extension to evaluate the long-term safety and efficacy of tadalafil in Japanese men with signs and symptoms of benign prostatic hyperplasia. www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [Cited 2009 April; 21] Available from: http: //ClinicalTrials.gov/show/NCT00783094 NLM Identifier: NCT00783094.
26. Eli Lilly and Company. A phase 3, randomized, double-blind, placebo-controlled, parallel-design study to evaluate the safety and efficacy of daily tadalafil for 12 weeks in men with signs and symptoms of benign prostatic hyperplasia on concomitant alpha1- adrenergic blocker therapy. www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [Cited 2009 April; 21] Available from: http: //ClinicalTrials.gov/show/ NCT00848081 NLM Identifier: NCT00848081.
27. Eli Lilly and Company. A phase 3, randomized, double blind, placebo and tamsulosin controlled, parallel design, multinational study to evaluate the efficacy and safety of tadalafil once a day dosing for 12 weeks in Asian men with signs and symptoms of benign prostatic hyperplasia. www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [Cited 2009 April; 21] Available from: http://ClinicalTrials.gov/show/NCT00861757 NLM Identifier: NCT00861757.
28. Eli Lilly and Company. A randomized, double-blind, placebo-controlled, parallel design, multinational study to evaluate the efficacy and safety of tadalafil 2.5 and 5 mg once daily dosing for 12 weeks for the treatment of erectile dysfunction and signs and symptoms of benign prostatic hyperplasia in men with both erectile dysfunction and benign prostatic hyperplasia. www.Clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April; 21] Available from: http://ClinicalTrials.gov/ show/NCT00855582 NLM Identifier: NCT00855582.
29. Orhan I, Onur R, Taşdemir C, Ayar A, Kadioǧlu A. Sildenafil citrate inhibits agonist induced contractions in isolated rat seminal vesicles. J Urol 2006; 175(6): 2350-2353 (Pubitemid 43668537)
30. Gajar SA, Tano T, Resende AC, Bitencourt JA, de Lemos Neto M, Damião R, et al. Inhibitory effect of sildenafil on the human isolated seminal vesicle. BJU Int 2007 Dec; 100(6): 1322-1325 (Pubitemid 350043930)
31. Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA. Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J Sex Med 2009; 6(2): 408-414
32. Wang WF, Wang Y, Minhas S, Ralph DJ. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 2007; 14(4): 331-335 (Pubitemid 46669039)
33. Mattos RM, Marmo Lucon A, Srougi M. Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008; 80(2): 162-5.
34. Hosseini MM, Yarmohammadi H. Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int 2007; 79(1): 28-32.
35. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med 2006; 3(6): 1077-1084 (Pubitemid 44644720)
36. Johns Hopkins University, Eli Lilly and Company. Tadalafil for treatment of priapism in men with sickle cell anemia. www. clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [Cited 2009 April; 21] Available from: http: //Clinical Trials.gov/show/NCT00538564 NLM Identifier: NCT00538564.
37. Ali ST, Rakkah NI. Neurophysiological role of sildenafil citrate (Viagra) on seminal parameters in diabetic males with and without neuropathy. Pak J Pharm Sci 2007; 20(1): 36-42.
38. Mostafa T. In vitro sildenafil citrate use as a sperm motility stimulant. Fertil Steril 2007; 88(4): 994-996
39. Pomara G, Morelli G, Canale D, Turchi P, Caglieresi C, Moschini C, et al. Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men. Fertil Steril 2007; 88(4): 860-865 (Pubitemid 47498359)
40. Jarvi K, Dula E, Drehobl M, Pryor J, Shapiro J, Seger M. Daily vardenafil for 6 months has no detrimental effects on semen characteristics or reproductive hormones in men with normal baseline levels. J Urol 2008; 179(3): 1060-1065
41. Hellstrom WJ, Gittelman M, Jarow J, Steidle C, McMurray J, Talley D, et al. An evaluation of semen characteristics in men 45 years of age or older after daily dosing with tadalafil 20mg: results of a multicenter, randomized, double-blind, placebo-controlled, 9- month study. Eur Urol 2008; 53(5): 1058-1065
42. Glenn DR, McVicar CM, McClure N, Lewis SE. Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro. Fertil Steril 2007; 87(5): 1064-1070 (Pubitemid 46659924)
43. Glenn DR, McClure N, Cosby SL, Stevenson M, Lewis SE. Sildenafil citrate (Viagra) impairs fertilization and early embryo development in mice. Fertil Steril 2009; 91(3): 893-899
44. Gratzke C, Uckert S, Kedia G, Reich O, Schlenker B, Seitz M, et al. In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 2007; 35(1): 49-5.
45. Yencilek F, Aktas C, Goktas C, Yilmaz C, Yilmaz U, Sarica K. Role of papaverine hydrochloride administration in patients with intractable renal colic: randomized prospective trial. Urology 2008; 72(5): 987-990
46. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002; 283(3): H1263-9. (Pubitemid 34941065)
47. Kukreja RC, Salloum F, Das A, Ockaili R, Yin C, Bremer YA, et al. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 2005; 42(5-6): 219-232 (Pubitemid 40726325)
48. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC. Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/ reperfusion injury via opening of mitochondrial K+ (ATP) channels in rabbits. J Mol Cell Cardiol 2006; 40(3): 405-411 (Pubitemid 43277842)
49. Sesti C, Florio V, Johnson EG, Kloner RA. The phosphodiesterase- 5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 2007; 19(1): 55-61. (Pubitemid 46067349)
50. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC. ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 2009; [Epub ahead of print].
51. Koneru S, Varma Penumathsa S, Thirunavukkarasu M, Vidavalur R, Zhan L, Singal PK, et al. Sildenafil-mediated neovascularization and protection against myocardial ischaemia reperfusion injury in rats: role of VEGF/angiopoietin-1. J Cell Mol Med 2008; 12(6B): 2651-2664
52. Jamnicki-Abegg M, Weihrauch D, Chiari PC, Krolikowski JG, Pagel PS, Warltier DC, et al. Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. J Cardiovasc Pharmacol 2007; 50(6): 670-676 (Pubitemid 350307037)
53. Pérez NG, Piaggio MR, Ennis IL, Garciarena CD, Morales C, Escudero EM, et al. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction. Hypertension 2007; 49(5): 1095-1103 (Pubitemid 351664333)
54. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, et al. Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 2007; 42(2): 453-458 (Pubitemid 46135606)
55. Rosanio S, Ye Y, Atar S, Rahman AM, Freeberg SY, Huang MH, et al. Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin. 2006; 20(1): 27-36.
56. du Toit EF, Rossouw E, Salie R, Opie LH, Lochner A. Effect of sildenafil on reperfusion function, infarct size, and cyclic nucleotide levels in the isolated rat heart model. Cardiovasc Drugs Ther 2005; 19(1): 23-31.
57. Bremer YA, Salloum F, Ockaili R, Chou E, Moskowitz WB, Kukreja RC. Sildenafil citrate (viagra) induces cardioprotective effects after ischemia/reperfusion injury in infant rabbits. Pediatr Res 2005; 57(1): 22-27 (Pubitemid 40039888)
58. Maas O, Donat U, Frenzel M, Rütz T, Kroemer HK, Felix SB, et al. Vardenafil protects isolated rat hearts at reperfusion dependent on GC and PKG. Br J Pharmacol 2008; 154(1): 25-31.
59. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008; 294(3): H1398-406.
60. Hsu S, Nagayama T, Koitabashi N, Zhang M, Zhou L, Bedja D, et al. Phosphodiesterase 5 inhibition blocks pressure overload-induced cardiac hypertrophy independent of the calcineurin pathway. Cardiovasc Res 2009; 81(2): 301-309
61. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 2009; 119(2): 408-420
62. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 2008; 10(12): 1158-1165
63. Pokreisz P, Vandenwijngaert S, Bito V, Van den Bergh A, Lenaerts I, Busch C, et al. Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice. Circulation 2009; 119(3): 408-416
64. Behling A, Rohde LE, Colombo FC, Goldraich LA, Stein R, Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 2008; 14(3): 189-197
65. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 2007; 50(22): 2136-2144 (Pubitemid 350117342)
66. Bussotti M, Montorsi P, Amato M, Magini A, Baldassarre D, Tantardini F, et al. Sildenafil improves the alveolar-capillary function in heart failure patients. Int J Cardiol 2008; 126(1): 68-72.
67. Guazzi M, Arena R, Pinkstaff S, Guazzi MD. Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 2008; [Epub ahead of print].
68. Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007; 115(1): 59-66. (Pubitemid 46058612)
69. Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. Int J Cardiol 2009 Mar 27 [Epub ahead of print].
70. MetroHealth Medical Center, GCRC. Single dose sildenafil in heart failure patients improves 6-minute walk test by a reduction in left ventricular filling pressure. www.clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April; 21] Available from: http: //ClinicalTrials.gov/show/ NCT00781508 NLM Identifier: NCT00781508.
71. National Heart Lung and Blood Institute (NHLBI), Pfizer. Phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX). www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April; 21] Available from: http: //Clinical Trials.gov/show/NCT00763867 NLM Identifier: NCT00763867.
72. Massachusetts General Hospital. Phase 3 study of the effects of chronic sildenafil citrate therapy on exercise tolerance and hemodynamics in patients with advanced heart failure. www. clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April; 21] Available from: http://Clinical Trials.gov/show/NCT00309790 NLM Identifier: NCT00309790.
73. Oliver JJ, Melville VP, Webb DJ. Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 2006; 48(4): 622-627 (Pubitemid 44843865)
74. Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 2006; 83(7): 1213-1219 (Pubitemid 43668004)
75. Li L, Jiang Q, Zhang L, Ding G, Gang Zhang Z, Li Q, et al. Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke. Brain Res 2007; 1132(1): 185-192 (Pubitemid 46096440)
76. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, et al. Angiogenesis detected after embolic stroke in rat brain using magnetic resonance T2*WI. Stroke 2008; 39(5): 1563-1568
77. Ding G, Jiang Q, Li L, Zhang L, Zhang ZG, Ledbetter KA, et al. Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats. J Cereb Blood Flow Metab 2008; 28(8): 1440-1448
78. Caretti A, Bianciardi P, Ronchi R, Fantacci M, Guazzi M, Samaja M. Phosphodiesterase-5 inhibition abolishes neuron apoptosis induced by chronic hypoxia independently of hypoxia-inducible factor-1alpha signaling. Exp Biol Med (Maywood) 2008; 233(10): 1222-1230
79. Henry Ford Health System. Phase 1 study of sildenafil (Viagra) treatment of subacute ischemic stroke. www.clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April; 21] Available from: http: //ClinicalTrials. gov/ show/NCT00452582 NLM Identifier: NCT00452582.
80. Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev 2009; 25(2): 136-143
81. Behr-Roussel D, Oudot A, Caisey S, Coz OL, Gorny D, Bernabé J, et al. Daily treatment with sildenafil reverses endothelial dysfunction and oxidative stress in an animal model of insulin resistance. Eur Urol 2008; 53(6): 1272-1280 (Pubitemid 351615453)
82. Konstantinopoulos A, Giannitsas K, Athanasopoulos A, Spathas D, Perimenis P. The impact of daily sildenafil on levels of soluble molecular markers of endothelial function in plasma in patients with erectile dysfunction. Expert Opin Pharmacother 2009; 10(2): 155-160
83. Burnett AL, Strong TD, Trock BJ, Jin L, Bivalacqua TJ, Musicki B. Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction. J Urol 2009; 181(1): 245-251
84. Rossi R, Nuzzo A, Lattanzi A, Coppi F, Modena MG. Sildenafil improves endothelial function in patients with pulmonary hypertension. Pulm Pharmacol Ther 2008; 21(1): 172-177
85. Morano S, Mandosi E, Fallarino M, Gatti A, Tiberti C, Sensi M, et al. Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. Eur Urol 2007; 52(6): 1768-1774 (Pubitemid 350052399)
86. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19(2): 200-207 (Pubitemid 46340840)
87. Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R, et al. Erectile dysfunction in systemic sclerosis: effects of long-term inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007; 34(8): 1712-1717 (Pubitemid 47267615)
88. Foresta C, Ferlin A, De Toni L, Lana A, Vinanzi C, Galan A, et al. Circulating endothelial progenitor cells and endothelial function after chronic Tadalafil treatment in subjects with erectile dysfunction. Int J Impot Res 2006; 18(5): 484-488 (Pubitemid 44330301)
89. Mazo E, Gamidov S, Iremashvili V. The effect of vardenafil on endothelial function of brachial and cavernous arteries. Int J Impot Res 2006; 18(5): 464-469 (Pubitemid 44330297)
90. Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ, et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev 2009; 25(2): 136-143
91. Hatzichristou D, Gambla M, Rubio-Aurioles E, Buvat J, Brock GB, Spera G, et al. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. Diabet Med 2008; 25(2): 138-146 (Pubitemid 351297651)
92. Wareing M, Myers JE, O'Hara M, Kenny LC, Taggart MJ, Skillern L, et al. Phosphodiesterase-5 inhibitors and omental and placental small artery function in normal pregnancy and pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2006; 127(1): 41-49 (Pubitemid 43947425)
93. Turgut NH, Temiz TK, Bagcivan I, Turgut B, Gulturk S, Karadas B. The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model. Eur J Pharmacol 2008; 589(1-3): 180-187
94. Pinheiro da Costa BE, Scocco C, Poli de Figueiredo CE, Guimarães JA. Increased serum phosphodiesterase activity in women with preeclampsia. BJOG 2006; 113(5): 577-579
95. Caruso S, Rugolo S, Agnello C, Intelisano G, Di Mari L, Cianci A. Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. Fertil Steril 2006; 85(5): 1496-1501
96. Ferrara D, Zaslau S. Success of sildenafil treatment in neurogenic female sexual dysfunction caused by L5-S1 intervertebral disk rupture: a case report. Int J Urol 2007; 14(6): 566-567 (Pubitemid 46985522)
97. Nurnberg HG, Hensley PL, Heiman JR, Croft HA, Debattista C, Paine S. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008; 300(4): 395-404. (Pubitemid 352040251)
98. van der Made F, Bloemers J, Yassem WE, Kleiverda G, Everaerd W, van Ham D, et al. The influence of testosterone combined with a PDE5-inhibitor on cognitive, affective, and physiological sexual functioning in women suffering from sexual dysfunction. J Sex Med 2009; 6(3): 777-790
99. van der Made F, Bloemers J, van Ham D, El Yassem W, Kleiverda G, Everaerd W, et al. Childhood sexual abuse, selective attention for sexual cues and the effects of testosterone with or without vardenafil on physiological sexual arousal in women with sexual dysfunction: a pilot study. J Sex Med 2009; 6(2): 429-439
100. Yang CC, Cao YY, Guan QY, Heiman JR, Kuffel SW, Peterson BT, et al. Influence of PDE5 inhibitor on MRI measurement of clitoral volume response in women with FSAD: a feasibility study of a potential technique for evaluating drug response. Int J Impot Res 2008; 20(1): 105-110
101. Claret L, Cox EH, McFadyen L, Pidgen A, Johnson PJ, Haughie S, et al. Modeling and simulation of sexual activity daily diary data of patients with female sexual arousal disorder treated with sildenafil citrate (Viagra). Pharm Res 2006; 23(8): 1756-1764 (Pubitemid 44200539)
102. Ambach A, Seo W, Bonnekoh B, Gollnick H. Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges 2009; [Epub ahead of print].
103. Little JA, Hauser KP, Martyr SE, Harris A, Maric I, Morris CR, et al. Hematologic, biochemical, and cardiopulmonary effects of Larginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2009; 82(4): 315-321
104. Hohenstein B, Daniel C, Wittmann S, Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant 2008; 23(11): 3427-3436
105. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, et al. Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 2009; 257(3): 137-43.
106. Lau DH, Mikhailidis DP, Thompson CS. The effect of vardenafil (a PDE type 5 inhibitor) on renal function in the diabetic rabbit: a pilot study. In Vivo 2007; 21(5): 851-854
107. Jeong KH, Lee TW, Ihm CG, Lee SH, Moon JY, Lim SJ. Effects of sildenafil on oxidative and inflammatory injuries of the kidney in streptozotocin-induced diabetic rats. Am J Nephrol 2009; 29(3): 274-282
108. Yoon MH, Park KD, Lee HG, Kim WM, An TH, Kim YO, et al. Additive antinociception between intrathecal sildenafil and morphine in the rat formalin test. J Korean Med Sci 2008; 23(6): 1033-1038
109. Yoon MH, Kim CM, Lee HG, Kim WM, An TH, Kim YO, et al. Synergistic antinociception of intrathecal sildenafil with clonidine in the rat formalin test. Pharmacol Biochem Behav 2009; [Epub ahead of print].
110. Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D. The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon. Clin Pharmacol Ther 2007; 81(4): 503-509 (Pubitemid 46452307)
111. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006; 166(2): 231-233 (Pubitemid 43144949)
112. Northwestern University, Eli Lilly and Company. Tadalafil for the treatment of secondary Raynaud's phenomenon. www.clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April 21] Available from: http: //Clinical Trials.gov/show/NCT00822354 NLM Identifier: NCT00822354.
113. Groeneweg G, Huygen FJ, Niehof SP, Wesseldijk F, Bussmann JB, Schasfoort FC, et al. Effect of tadalafil on blood flow, pain, and function in chronic cold Complex Regional Pain Syndrome: a randomized controlled trial. BMC Musculoskelet Disord 2008; 9: 143.
114. Rutten K, Van Donkelaar EL, Ferrington L, Blokland A, Bollen E, Steinbusch HW, et al. Phosphodiesterase Inhibitors Enhance Object Memory Independent of Cerebral Blood Flow and Glucose Utilization in Rats. Neuropsychopharmacology 2009; [Epub ahead of print].
115. Rutten K, Basile JL, Prickaerts J, Blokland A, Vivian JA. Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques. Psychopharmacology (Berl) 2008; 196(4): 643-648
116. Rutten K, Vente JD, Sik A, Ittersum MM, Prickaerts J, Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav Brain Res 2005; 164(1): 11-16 (Pubitemid 41253727)
117. van Donkelaar EL, Rutten K, Blokland A, Akkerman S, Steinbusch HW, Prickaerts J. Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. Eur J Pharmacol 2008; 600(1-3): 98-104.
118. Goff DC, Cather C, Freudenreich O, Henderson DC, Evins AE, Culhane MA, et al. A placebo-controlled study of sildenafil effects on cognition in schizophrenia. Psychopharmacology (Berl) 2009; 202(1-3): 411-417
119. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008; 1230: 290-302.
120. Hamamatsu University. Randomized phase II study of combination chemotherapy with sildenafil plus carboplatin and weekly paclitaxel in patients with previously untreated advanced non-small cell lung cancer. In: Clinical trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April 21] Available from: http: //ClinicalTrials.gov/show/ NCT00752115 NLM Identifier: NCT00752115.
121. Dormer RL, Harris CM, Clark Z, Pereira MM, Doull IJ, Norez C, et al. Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax 2005; 60(1): 55-59 (Pubitemid 40101019)
122. Lubamba B, Lecourt H, Lebacq J, Lebecque P, De Jonge H, Wallemacq P, et al. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. Am J Respir Crit Care Med 2008; 177(5): 506-515
123. University of New Mexico. The role of phosphodiesterase inhibitors in CF lung disease www.clinicaltrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2009 April 21] Available from: http: //ClinicalTrials.gov/show/NCT00659529 NLM Identifier: NCT00659529.
124. Graça JR, Macedo GM, Palheta RC Jr, Gondim Fde A, Nogueira RO, Correia JM, et al. Sildenafil delays the intestinal transit of a liquid meal in awake rats. Braz J Med Biol Res 2008; 41(1): 78-81.
125. Zhu H, Xu X, Chen JD. Inhibitory effects of sildenafil on gastric motility and gastric slow waves in dogs. Neurogastroenterol Motil 2007; 19(3): 218-224 (Pubitemid 46239434)
126. Cho SH, Park H, Kim JH, Ryu YH, Lee SI, Conklin JL. Effect of sildenafil on gastric emptying in healthy adults. J Gastroenterol Hepatol 2006; 21(1 Pt 2): 222-226
127. Medeiros JV, Gadelha GG, Lima SJ, Garcia JA, Soares PM, Santos AA, et al. Role of the NO/cGMP/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats. Br J Pharmacol 2008; 153(4): 721-727
128. Derici H, Kamer E, Unalp HR, Diniz G, Bozdag AD, Tansug T, et al. Effect of sildenafil on wound healing: an experimental study. Langenbecks Arch Surg 2009 Feb 18 [Epub ahead of print].
129. Irkorucu O, Ucan BH, Cakmak GK, Emre AU, Tascilar O, Ofluoglu E, et al. Does sildenafil reverse the adverse effects of ischemia on ischemic colon anastomosis: yes, 'no'. Int J Surg 2009; 7(1): 39-43.
130. Uzun H, Konukoglu D, Nuri MK, Ersoy EY, Ozçevik S, Yavuz N. The effects of sildenafil citrate on ischemic colonic anastomotic healing in rats: its relationship between nitric oxide and oxidative stress. World J Surg 2008; 32(9): 2107-2113
131. Ayten R, Cetinkaya Z, Girgin M, Ozercan I, Ustundag B, Aygen E. The effects of intraperitoneal sildenafil administration on healing of left colonic anastomoses and intra-abdominal adhesion formation in the presence of intra-abdominal infection. Dis Colon Rectum 2008; 51(12): 1837-1841
132. Aversa A, Caprio M, Rosano GM, Spera G. Endothelial effects of drugs designed to treat erectile dysfunction. Curr Pharm Des 2008; 14(35): 3768-3778
133. Srivani P, Usharani D, Jemmis ED, Sastry GN. Subtype selectivity in phosphodiesterase 4 (PDE4): a bottleneck in rational drug design. Curr Pharm Des 2008; 14(36): 3854-3872
134. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des 2009; 15(14): 1688-1698